Clinical Trials Logo

Clinical Trial Summary

The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04572243
Study type Interventional
Source Eisai Inc.
Contact Eisai Medical Information
Phone 1-888-274-2378
Email esi_medinfo@eisai.com
Status Recruiting
Phase Phase 3
Start date September 23, 2020
Completion date May 28, 2025

See also
  Status Clinical Trial Phase
Available NCT04457687 - Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies